A Long-Term follow-up Study to evaluate safety and tolerability of olipudase alfa in patients who completed the DFI12712 or the LTS13632 Study in France - PTA17397

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515304-39-00

Acronym

PTA17397

Enrollment

Registered

2024-08-02

Start date

2021-11-18

Completion date

2025-04-08

Last updated

2024-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Niemann-Pick disease

Brief summary

Number of adverse events (AEs) / serious adverse events (SAEs)

Interventions

DRUGXenpozyme (olipudase alfa

DRUGGZ402665)

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of adverse events (AEs) / serious adverse events (SAEs)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026